By Deborah Gage Print this article Print

The drug maker's best-seller has some nasty side effects. A voice recognition system helps patients, doctors and pharmacists manage the risk.

Celgene Base Case">

Celgene Base Case Headquarters: 86 Morris Ave., Summit, NJ 07901
Phone: (908) 673-9000
Business: Discovering, developing and commercializing pharmaceuticals
Information Technology Director: Steve Lerner
Financials in 2004: $377.5 million in revenue; $52.8 million in net income.
Challenge: To put in place an information system that will help prevent drug side effects such as birth defects, miscarriages and blood clots.

  • Boost revenue by 39% to $525 million in 2005, from $377.5 million in 2004.
  • Generate $400 million in sales of Thalomid in 2005, an increase of 29.6% from $308.6 million in 2004.
  • Raise R&D spending by 24.3% to $200 million in 2005, from $160.9 million the previous year.
  • Increase selling, general and administrative expenses to $175 million in 2005, from $114.2 million in 2004, to support the launch of Revlimid.

This article was originally published on 2005-12-06
Senior Writer
Based in Silicon Valley, Debbie was a founding member of Ziff Davis Media's Sm@rt Partner, where she developed investigative projects and wrote a column on start-ups. She has covered the high-tech industry since 1994 and has also worked for Minnesota Public Radio, covering state politics. She has written freelance op-ed pieces on public education for the San Jose Mercury News, and has also won several national awards for her work co-producing a documentary. She has a B.A. from Minnesota State University.

eWeek eWeek

Have the latest technology news and resources emailed to you everyday.